Russian Scientists Develop Hybrid Molecules That Evade Cancer Drug Resistance
Key Insights
Russian researchers have synthesized hybrid oxadiazole-tetrazole molecules that block EGFR in drug-resistant cancer (search) cells by binding outside the mutated active site.
In cell culture experiments, the chlorine-containing compound proved 1.5 times more effective than osimertinib against resistant tumor cell lines.
The molecules were tested across lung, liver, colon, and breast cancer (search) cell lines, with computer modeling also assessing solubility and toxicity profiles.
A team of Russian researchers has developed a novel class of hybrid molecules capable of suppressing tumor cell growth even in cancers that have acquired resistance to existing targeted therapies. The compounds, built around an oxadiazole core with a tetrazole ring and flexible molecular bridges, demonstrated 1.5-fold greater efficacy than osimertinib — one of the newest and most expensive drugs for resistant tumors — in cell culture experiments. The findings, published in the journal Synthetic Communications, could lay the groundwork for a new generation of anticancer agents.
Cancer (search) claims nearly 10 million lives each year globally. While conventional chemotherapy remains effective, it causes severe side effects by destroying healthy cells alongside malignant ones. A more intractable problem is acquired drug resistance: cancer cells develop genetic mutations that render once-effective therapies obsolete. Many modern chemotherapeutics, including erlotinib and gefitinib, target the epidermal growth factor receptor (search) (EGFR), a protein that is overactive in cancer cells and drives uncontrolled proliferation. When EGFR mutates, these drugs lose their grip on the target.
A Multi-Pronged Binding Strategy
Researchers from the Russian Presidential Academy of National Economy and Public Administration (search), together with collaborators, designed hybrid molecules that overcome this limitation by engaging EGFR at multiple contact points. The core scaffold is oxadiazole — a heterocyclic ring containing carbon, oxygen, and nitrogen atoms. To this, the scientists appended a tetrazole ring that forms strong hydrogen bonds within the receptor's active site. A flexible molecular bridge then extends additional chemical groups, including a chlorine-bearing moiety, to reach binding regions outside the active center.
This architectural strategy means the molecules maintain affinity for EGFR even when the canonical binding pocket is altered by mutation. "In medicinal chemistry, a drug molecule must fit its receptor like a key in a lock," said Olga Mikolaichuk, project leader and senior researcher at the Russian Presidential Academy of National Economy and Public Administration (search). "We have found just such an ideal key. It turned out that adding just one element — chlorine — to the molecular structure makes it most effective at stopping tumour cell division and triggering cell death."
The researchers liken the mechanism to a key with multiple notches engaging different parts of a lock: even if one protrusion is missing due to mutation, the remaining contact points still allow the door to open.
Preclinical Efficacy Across Multiple Cancer (search) Types
The hybrid molecules were tested against a panel of cancer (search) cell lines representing lung, liver, colon, and breast cancers. The chlorine-free variant achieved cancer cell killing at concentrations comparable to osimertinib. The chlorine-containing analog, however, surpassed osimertinib by a factor of 1.5 in potency against resistant cells.
Beyond in vitro efficacy, the team employed computer modeling to predict the compounds' behavior in the human body, evaluating solubility characteristics and potential toxicity to healthy tissues. These in silico assessments provide an early pharmacokinetic and safety profile that will guide further development.
Next Steps Toward Clinical Translation
The research team's immediate plans focus on improving the drug-like properties of the lead molecules. "Next, we plan to combine the most active molecules with the protein albumin to reduce the risk of severe allergic reactions and improve treatment tolerability," Mikolaichuk explained. "This technology is already used in some modern anticancer drugs, such as Abraxane."
The albumin-conjugation strategy mirrors the approach used in nab-paclitaxel (Abraxane), where nanoparticle albumin-bound formulations enhance drug delivery and reduce hypersensitivity reactions. If successful, this could transform the hybrid molecules into viable therapeutic candidates for patients whose cancers no longer respond to standard EGFR-targeted therapy.